Want to see VIR full AI Analyst Report?
VIR Stock Chart & Stats
$10.75
$5.76(73.00%)
At close: 4:00 PM EST
$10.75
$5.76(73.00%)
Day’s Range― - ―
52-Week Range$4.16 - $11.66
Previous CloseN/A
Volume25.73M
Average Volume (3M)2.06M
Market Cap
$1.56B
Enterprise Value$937.67
Total Cash (Recent Filing)$472.36M
Total Debt (Recent Filing)$95.58M
Price to Earnings (P/E)―
Beta0.68
Next Earnings
Jul 30, 2026EPS Estimate
0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.13
Shares Outstanding168,651,980
10 Day Avg. Volume1,634,536
30 Day Avg. Volume2,058,174
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)1.09
Price to Sales (P/S)12.18
P/FCF Ratio-2.11
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$21.43Price Target Upside99.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-1.93
Revenue Forecast (FY)$161.89M
Bulls Say, Bears Say
Bulls Say
Strategic Partnership & Upfront FundingThe Astellas collaboration provides multi‑hundred million near‑term proceeds and a milestone backbone, materially de‑risks VIR‑5500 development funding. Partner technical/commercial resources and profit‑share lower solo commercialization burden and extend strategic optionality over several years.
Balance Sheet Strength & RunwayA large cash balance combined with recent equity financing and upfront partner proceeds gives the company multi‑year runway to conduct registrational trials and pursue partnerships. Low leverage (debt/equity ~0.11) preserves financial flexibility versus highly indebted peers.
HDV Clinical Efficacy & Regulatory SupportRobust SOLSTICE results plus Breakthrough/Fast Track and EMA PRIME/orphan designations create a durable regulatory path and potential premium pricing for an orphan indication. Multiple registrational ECLIPSE trials build a defensible clinical dossier and support commercial launch planning.
Bears Say
Collapsed Revenue & Persistent LossesTop‑line has contracted to a largely milestone/partner revenue base while operating losses and negative free cash flow persist. This structural revenue volatility forces ongoing reliance on collaborations and financings, limiting self‑funding and increasing execution dependency on partner milestones.
HDV Market Access & Approval ComplexityUnderdiagnosis structurally constrains addressable patients absent screening changes, while regulators asking for multiple pivotal datasets lengthens time‑to‑approval and raises development cost. Combined, these factors increase commercialization risk and delay revenue realization for HDV therapies.
T Cell Engager Class Safety & Execution RiskClass‑level toxicities and prior competitor program discontinuations create persistent program risk for VIR's PROXTEN T cell engagers. Safety surprises or ambiguous pivotal success criteria can force additional studies, slow timelines, and boost R&D spend, pressuring scarce resources and execution certainty.
Vir Biotechnology News
VIR FAQ
What was Vir Biotechnology’s price range in the past 12 months?
Vir Biotechnology lowest stock price was $4.16 and its highest was $11.66 in the past 12 months.
What is Vir Biotechnology’s market cap?
Vir Biotechnology’s market cap is $1.56B.
When is Vir Biotechnology’s upcoming earnings report date?
Vir Biotechnology’s upcoming earnings report date is Jul 30, 2026 which is in 8 days.
How were Vir Biotechnology’s earnings last quarter?
Vir Biotechnology released its earnings results on May 06, 2026. The company reported -$0.85 earnings per share for the quarter, missing the consensus estimate of -$0.096 by -$0.754.
Is Vir Biotechnology overvalued?
According to Wall Street analysts Vir Biotechnology’s price is currently Undervalued.
Does Vir Biotechnology pay dividends?
Vir Biotechnology does not currently pay dividends.
What is Vir Biotechnology’s EPS estimate?
Vir Biotechnology’s EPS estimate is 0.33.
How many shares outstanding does Vir Biotechnology have?
Vir Biotechnology has 168,651,980 shares outstanding.
What happened to Vir Biotechnology’s price movement after its last earnings report?
Vir Biotechnology reported an EPS of -$0.85 in its last earnings report, missing expectations of -$0.096. Following the earnings report the stock price went down -9.913%.
Which hedge fund is a major shareholder of Vir Biotechnology?
Currently, no hedge funds are holding shares in VIR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vir Biotechnology Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.43 (99.34% Upside)
$21.43 (99.34% Upside)
Blogger Sentiment
Bullish
VIR Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 48.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 0.6%
Last 30 Days ▲ 3.0%
Last 30 Days ▲ 3.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
70.60%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-21.57%
Trailing 12-Months
Company Description
Vir Biotechnology
Vir Biotechnology, Inc. operates as an immunology company with commercialized products, dedicated to devising therapeutic solutions for the treatment and prevention of significant infectious diseases. Its pipeline features several key candidates: Sotrovimab (branded as Xevudy, or VIR-7832), a neutralizing monoclonal antibody for both treating and preventing SARS-CoV-2 infection; VIR-2218 and VIR-3434, aimed at hepatitis B virus; VIR-2482, targeting the prevention of influenza A virus; and VIR-1111, designed to prevent human immunodeficiency virus. The firm maintains a robust network of strategic partnerships and collaborations. These include grant support from organizations like the Bill & Melinda Gates Foundation and the National Institutes of Health. It holds option and licensing arrangements with entities such as Brii Biosciences Limited, and a collaboration and license agreement with Alnylam Pharmaceuticals, Inc. Further licensing relationships exist with The Rockefeller University and MedImmune, Inc. Collaborations extend to WuXi Biologics and Glaxo Wellcome UK Ltd., alongside a research agreement with GlaxoSmithKline Biologicals SA. Furthermore, Vir has secured a manufacturing contract with Samsung Biologics Co.,Ltd. for SARS-CoV-2 antibodies and a clinical development partnership with Gilead Sciences, Inc. focused on chronic hepatitis B virus. The company, established in 2016, is headquartered in San Francisco, California.
VIR Stock 12 Month Forecast
Average Price Target
$21.43
▲(99.34% Upside)
Technical Analysis
Ownership Overview
10.11% Insiders
13.87% Mutual Funds
0.04% Other Institutional Investors
52.80% Public Companies and
Individual Investors